A5032784879- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Spondyloarthritis Studies and Treatments
- Psoriasis: Treatment and Pathogenesis
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Inflammatory Bowel Disease
- Microscopic Colitis
- Adolescent and Pediatric Healthcare
- Fibromyalgia and Chronic Fatigue Syndrome Research
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Autoimmune and Inflammatory Disorders
- Anesthesia and Pain Management
- Oral and gingival health research
- Inflammatory Myopathies and Dermatomyositis
- Drug-Induced Adverse Reactions
- Autoimmune Bullous Skin Diseases
- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- Health Systems, Economic Evaluations, Quality of Life
- Child and Adolescent Health
- Pharmaceutical studies and practices
- Immunodeficiency and Autoimmune Disorders
Bristol-Myers Squibb (Switzerland)
2016-2017
Abbott (France)
2012-2013
King's College Hospital NHS Foundation Trust
2012
King's College London
2012
Abbott (Germany)
2007-2008
Abbott (United Kingdom)
2008
University College London
2007
The University of Texas Southwestern Medical Center
1992-1998
Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid arthritis. We evaluated the efficacy and safety of adalimumab, fully human monoclonal anti-TNF antibody, children with polyarticular-course arthritis.Patients 4 to 17 years age active arthritis who had previously received treatment nonsteroidal antiinflammatory drugs underwent stratification according methotrexate use 24 mg adalimumab per square meter body-surface area (maximum dose, 40 mg) subcutaneously every other...
Abstract Objective. To delineate the phenotype and function of synovial T cells in rheumatoid arthritis (RA). Methods. from normal subjects or RA peripheral blood (PB), fluid (SF), tissue (ST) were analyzed phenotypically functionally. Results. SF ST found to be markedly enriched CD45RA dim , CD45RO+, CD45RB mature memory cells, whereas PB, bright naive more frequent than CD45RO+ only a minority . proliferated less well produced interleukin‐2 response mitogenic stimuli did PB cells. However,...
Abstract Positive and negative effects of CD40 ligation on human B cell function were suggested by the observation that mAb to ligand partially blocked suppressive influences anti-CD3-stimulated control CD4+ T cells, as well stimulatory anti-CD3 activated mitomycin C-treated cells. To examine in greater detail, cells cultured with expressed optimal levels ligand; additional recombinant significantly suppressed Ig production, but not proliferation. In contrast, when stimulated SAC...
Objective This study aimed to expand the understanding of patient with psoriatic arthritis (PsA) experience and compare/contrast clinician prioritization PsA dimensions. Methods We conducted four patients focus groups across three US rheumatology practices using mixed methods identify attributes important patients. Combination extant identified by a steering committee created comprehensive list attributes. In separate physician Delphi exercises, participants distributed 100 points items on...
<h3>Background</h3> Apremilast (APR), a PDE4 inhibitor, helps regulate immune responses in psoriatic arthritis (PsA). PALACE 1-3 compared APR efficacy/safety with placebo (PBO) patients (pts) active PsA despite prior conventional DMARDs and/or biologics, including efficacy assessment across multiple aspects of disease. Enthesitis and dactylitis are hallmark features that lead to pain disability. <h3>Objectives</h3> Evaluate the impact treatment over 104 wks on enthesitis pooled analysis 1-3....
<h3>Background</h3> As long-term treatment with anti-tumour necrosis factor (TNF) drugs becomes accepted practice, the risk assessment of prolonged administration requires understanding anti-TNF safety. Rates adverse events (AE) in patients (pts) treated therapy can vary across therapeutic indications due to differences disease-inherent risks, comorbidities, and use concomitant immunosuppressant drugs. <h3>Objectives</h3> To assess compare adalimumab's (ADA) safety profile through nearly 12...
Antibodies to the ligand for CD40 (CD154) have been shown exert profound effects on development of cell-mediated immune responses in mice. The present study shows that an antibody human CD154 (hCD40L) inhibits vivo Tetanus toxoid (TT) specific secondary hu-PBL-scid mice, as well expansion xenoreactive T cells scid A possible cause reduced xenoreactive, cells, was decreased expression murine B7.1 and B7.2 caused by administration anti-hCD40L. Therefore, it may be defective maturation...
<h3>Background</h3> Treatment goals for long-term control of skin and joint symptoms in active psoriatic arthritis (PsA) include clinically important changes DAS-28 (CRP), achievement remission reduction swollen count (SJC), decrease disease.<sup>1</sup> PALACE 3 included PsA patients with disease an lesion at the time enrollment. <h3>Objectives</h3> Report impact apremilast (APR) on manifestations over 4 years. <h3>Methods</h3> Patients were stratified by baseline (BL) DMARD use (yes/no)...
Antibodies to the ligand for CD40 (CD154) have been shown exert profound effects on development of cell-mediated immune responses in mice. The present study shows that an antibody human CD154 (hCD40L) inhibits vivo Tetanus toxoid (TT) specific secondary hu-PBL-scid mice, as well expansion xenoreactive T cells scid A possible cause reduced xenoreactive, cells, was decreased expression murine B7.1 and B7.2 caused by administration anti-hCD40L. Therefore, it may be defective maturation...
<h3>Background</h3> Treatment goals for active psoriatic arthritis (PsA) include long-term control of both skin and joint symptoms. Achievement remission in 28-joint count Disease Activity Score (DAS-28) using C-reactive protein (CRP), clinically important changes DAS-28 reduction swollen (SJC), or decrease disease may be used as treatment.<sup>1</sup> PALACE 3 (NCT01212770) included PsA patients with an lesion at the time enrollment. <h3>Objectives</h3> Assess treatment responses across...
<h3>Background</h3> In the PALACE psoriatic arthritis (PsA) trials, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score was obtained as an exploratory measure in a subset of patients (pts) considered by investigators to have axial involvement, although PsA spondylitis not confirmed more objective measures such MRI. <h3>Objectives</h3> Assess impact apremilast 30 mg BID (APR) on BASDAI over 52 wks using 1 (NCT01172938), 2 (NCT01212757), and 3 (NCT01212770) pooled data pts with...
<h3>Background</h3> Dactylitis and enthesitis, hallmark features of psoriatic arthritis (PsA), may be difficult to manage. PALACE 1, 2, 3 compared the efficacy safety apremilast (APR) with placebo (PBO) in patients (pts) active PsA despite prior conventional DMARDs and/or biologics. <h3>Objectives</h3> Report impact long-term APR 30 mg BID (APR30) treatment on dactylitis enthesitis pts PsA. <h3>Methods</h3> Pts were randomized (1:1:1) PBO, APR30, or 20 (APR20) stratified by baseline (BL)...
<h3>Background</h3> Improving and preserving patient (pt) physical function is an important goal for psoriatic arthritis (PsA). <h3>Objectives</h3> To evaluate apremilast9s (APR) effects on function/functional status up to 3 yrs in DMARD/biologic-experienced (PALACE 1–3 [PAL1–3] pooled data) DMARD-naive 4 [PAL4]) pts with active PsA. <h3>Methods</h3> Pts were randomized (1:1:1) placebo (PBO), APR 30 mg BID (APR30), or 20 (APR20) at baseline (BL). The primary endpoint was Wk16; a long-term...
creases laboratory tests and retains constant outpatient visits the usage of other drugs.
<h3>Background</h3> Psoriatic arthritis (PsA) reduces physical function and QoL; a treatment goal is to improve/maintain functionality. PALACE 1 (NCT01172938), 2 (NCT01212757), 3 (NCT01212770) compared apremilast (APR) efficacy/safety with placebo (PBO) in patients (pts) active PsA despite prior conventional DMARDs and/or biologics, providing one of the largest databases (N=1,489) examining disability pts moderate/severe PsA. <h3>Objectives</h3> Assess APR 30 mg BID (APR30) impact on using...
Background: Genome-wide association studies have revealed the polygenic nature of AS.More than 60 genetic influences been identified, but most these are non-coding sequences.Protection against AS is afforded by a loss functional mutation in cytoplasmic tail IL-23 receptor (IL-23R), there also second independent this region.This study explores basis for latter between and single nucleotide polymorphisms (SNPs) IL23R-IL12RB2 intergenic region.Methods: We performed conditional analysis on data...